A Multicenter, Randomized, Double-Blind, Titration Study to Evaluate and Compare the Efficacy and Safety of Ezetimibe 10 mg Added on to Rosuvastatin 5 mg, 10 mg, 20 mg, or 40 mg Versus Up-Titration Rosuvastatin 10 mg, 20 mg, or 40 mg in Hypercholesterolemic Patients at Moderately High and High Risk for Coronary Heart Disease
- Registry ID
- EUCTR2008-004953-14
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE3
- Sponsor
- Merck & Co., Inc.
- Start date
- 2009-01-16
- Completion date
- 2010-05-10
- Last update
- 2026-08-16
Conditions
Summary
To evaluate the LDL-C lowering efficacy of the addition of ezetimibe (10 mg) to rosuvastatin (5 or 10 mg) (pooled across doses) compared with doubling the baseline dose of rosuvastatin (pooled) in patients with primary hypercholesterolemia at moderately high or high risk for CHD, who are treated with rosuvastatin (5 or 10 mg) alone and not at their NCEP ATP III LDL-C goal.
Locations
- , , Finland
- , , Hungary
- , , Denmark
View on source registry